Matching articles for "Restless legs syndrome"
Issue 1526 · July 31, 2017
Drugs for Epilepsy

Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists…

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):121-30
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists generally recommend trying at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs concurrently. When used for the appropriate seizure type, AEDs are roughly equivalent in efficacy. Drug choice is usually based on factors such as ease of use, adverse effects, drug interactions, presence of comorbidities, and cost.
Issue 1397 · August 20, 2012 Free
In Brief: Transdermal Rotigotine (Neupro)

A patch formulation of the non-ergot dopamine agonist rotigotine ( Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early…

Med Lett Drugs Ther. 2012 Aug 20; 54(1397):68
A patch formulation of the non-ergot dopamine agonist rotigotine ( Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early Parkinson’s disease, 1 it was withdrawn in 2008 because of crystallization of the drug in the patch, which could have led to under-dosing. The new patch has somewhat broader indications than the old one; it is approved for use in any stage of Parkinson’s disease (PD) and also for moderate-to-severe restless legs syndrome (RLS). 1. Transdermal rotigotine (Neupro) for Parkinson’s disease. Med Lett Drugs Ther 2007; 49:69. Download complete U.S. English article
Issue 1372 · September 5, 2011
Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome

Gabapentin enacarbil ( Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome…

Med Lett Drugs Ther. 2011 Sep 5; 53(1372):70-1
Gabapentin enacarbil ( Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR) formulation of gabapentin ( Neurontin ,and others), which is approved for treatment of epilepsy and postherpetic neuralgia, has been used for many years to treat RLS. Another ER tablet formulation of gabapentin (Gralise) has been approved by the FDA for treatment of postherpetic neuralgia.
Issue 1257 · March 26, 2007
Pramipexole (Mirapex) for Restless Leg Syndrome

The dopamine agonist pramipexole ( Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip) , another…

Med Lett Drugs Ther. 2007 Mar 26; 49(1257):26-8
The dopamine agonist pramipexole ( Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip) , another dopamine agonist, was approved for RLS in 2005. Both of these drugs were first approved for treatment of Parkinson's disease.
Issue 1214 · August 1, 2005
Ropinirole for Restless Legs Syndrome

Ropinirole ( Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):62-4
Ropinirole ( Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).